miRNAs在肝细胞癌中的功能及应用前景

摘要
图/表
参考文献(28)
相关文章 (15)

全文: PDF (667 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肝细胞癌（HCC）是最常见的原发性肝脏恶性肿瘤，是全世界癌症死亡的主要原因之一，其显著特征是预后不良。因此，越来越多的研究集中于为HCC诊断和预后寻找新的分子标志物。microRNAs（miRNAs）是小的非编码RNA。表达失调的miRNAs其本身充当癌基因或肿瘤抑制基因，参与癌症的发生发展。新近研究发现，miRNAs的异常表达参与了HCC的许多生物过程，本文主要总结近年关于miRNAs在HCC肿瘤发生发展中作用的研究，为miRNAs用于HCC诊断、预后或作为治疗靶点提供理论依据。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈彩霞苏秀兰

关键词 ： microRNAs, 肝细胞癌, 诊断, 治疗

Abstract：Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and is one of the leading causes of cancer deaths in the world, it is characterized by a poor prognosis. More and more researches have focused on finding new molecular markers for HCC diagnosis and prognosis. microRNAs (miRNAs) is a sort of small and non-coding RNA. Deregulated miRNAs themselves act as oncogenes or tumor suppressor genes and are involved in the development and progression of cancer. Recent studies have found that the abnormal expression of many miRNAs is involved in many biological processes of HCC. This paper summarizes the studies on the role of miRNAs in the development and progression of HCC tumors in recent years, and provides a theoretical basis for the application of miRNAs in HCC diagnosis, prognosis or as a therapeutic target.

Key words： microRNAs Hepatocellular carcinoma Diagnosis Treatment

基金资助:国家自然科学基金资助项目（81660468）。

通讯作者: 苏秀兰（1956-），女，硕士，博士研究生导师，内蒙古医科大学附属医院临床医学研究中心主任；研究方向：肿瘤分子生物学机制。

作者简介: 陈彩霞（1990-），女，硕士；研究方向：抗肿瘤药物分子机制。

引用本文:

陈彩霞苏秀兰. miRNAs在肝细胞癌中的功能及应用前景[J]. 中国医药导报, 2018, 15(34): 37-40,48.
CHEN Caixia SU Xiulan. The function and application prospect of miRNAs in hepatocellular carcinoma. 中国医药导报, 2018, 15(34): 37-40,48.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I34/37

[1] Xiao XH，Lv LC，Duan J，et al. Regulating Cdc42 and Its Signaling Pathways in Cancer.Small Molecules and MicroRNA as New Treatment Candidates [J]. Molecules，2018， 23（4）：E787.
[2] Bracken CP，Scott HS，Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer [J]. Nat Rev Genet，2016，17（12）：719-732.
[3] Vasuri F，Visani M，Acquaviva G，et al. Role of microRNAs in the main molecular pathways of hepatocellular carcinomal [J]. World J Gastroenterol，2018，24（25）：2647-2660.
[4] Chen Y，Verfaillie CM. MicroRNAs：the fine modulators of liver development and function [J]. Liver Int，2014，34（7）：976-990.
[5] Gailhouste L，Gomez-Santos L，Hagiwara K，et al. miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells [J]. Hepatology，2013，58（3）：1153-1165.
[6] Liu AM，Xu Z，Shek FH，et al. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma [J]. PLoS One，2014，9（1）：e86872.
[7] Lu H，Lei X，Liu J，et al. Regulation of hepatic microRNA expression by hepatocyte nuclear factor 4 alpha [J]. World J Hepatol，2017，9（4）：191-208.
[8] Laudadio I，Manfroid I，Achouri Y，et al. A feedback loop between the liver-enriched transcript tion factor network and miR-122 controls hepatocyte differentiation [J]. Gastroenterology，2012，142（1）：119-129.
[9] Bandiera S，Pfeffer S，Baumert TF，et al. miR-122--a key factor and therapeutic target in liver disease [J]. J Hepatol，2015，62（2）：448-457.
[10] Sheneef A，Gouda AM，Mohammad AN，et al. Serum MicroRNA-122 and MicroRNA-155：Markers of Disease Progression in Hepatitis C viral infection [J]. Egypt J Immunol，2017，24（2）：33-46.
[11] Zhuang C，Jiang W，Huang D，et al. Serum miR-21，miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma [J]. Clin Res Hepatol Gastroenterol，2016， 40（4）：386-396.
[12] Tian T，Wang M，Zhu W，et al. MiR-146a and miR-196a-2 polymorphisms are associated with hepatitis virus-related hepatocellular cancer risk：a meta-analysis [J]. Aging （Albany NY），2017，9（2）：381-392.
[13] Mamdouh S，Khorshed F，Aboushousha T，et al. Evaluation of Mir-224，Mir-215 and Mir-143 as Serum Biomarkers for HCV Associated Hepatocellular Carcinoma [J]. Asian Pac J Cancer Prev，2017，18（11）：3167-3171.
[14] Xue F，Liang Y，Li Z，et al. MicroRNA-9 enhances sensitivity to cetuximab in epithelial phenotype hepatocellular carcinoma cells through regulation of the eukaryotic translation initiation factor 5A-2 [J]. Oncol Lett，2018， 15（1）：813-820.
[15] Hu H，Wang G，Li C. miR-124 suppresses proliferation and invasion of nasopharyngeal carcinoma cells through the Wnt/β-catenin signaling pathway by targeting Capn4 [J]. Onco Targets Ther，2017，10：2711-2720.
[16] Zhang X，Qiu S，Luo P，et al. Down-regulation of hsa_circ_0001649 in hepatocellular carcinoma predicts a poor prognosis [J]. Cancer Biomark，2018，22（1）：135-142.
[17] Vallianou I，Dafou D，Vassilaki N，et al. Hepatitis C virus suppresses Hepatocyte Nuclear Factor 4 alpha，a key regulator of hepatocellular carcinoma [J]. Int J Biochem Cell Biol，2016，78：315-326.
[18] Ning BF，Ding J，Liu J，et al. Hepatocyte nuclear factor 4α-nuclear factor-κB feedback circuit modulates liver cancer progression [J]. Hepatology，2014，60（5）：1607-1619.
[19] Zekri AN，Youssef AS，El-Desouky ED，et al. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection [J]. Tumour Biol，2016，37（9）：12273-12286.
[20] Okajima W，Komatsu S，Ichikawa D，et al. Circulating microRNA profiles in plasma：identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function [J]. Oncotarget，2016，7（33）：53820-53836.
[21] Gao B，Gao K，Li L，et al. miR-184 functions as an oncogenic regulator in hepatocellular carcinoma（HCC）[J]. Biomed Pharmacother，2014，68（2）：143-148.
[22] Zhao N，Wang R，Zhou L，et al. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3 [J]. Mol Cancer，2014，13：35.
[23] Hany A. Omar，Mai F. Tolba，Jui-Hsiang Hung，et al. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma：The Role of PKCδ/p53 [J]. Front Pharmacol，2016，7：463.
[24] Ye C，Sun NX，Ma Y，et al. MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells [J]. FEBS Lett，2015，589（6）：702-709.
[25] Zhou S，Ye W，Ren J，et al. MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma [J]. Am J Cancer Res，2015，5（1）：267-277.
[26] Wang Q，Qin J，Chen A，et al. Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer [J]. Tumour Biol，2015，36（5）：3703-3708.
[27] Li S，Yao J，Xie M，et al. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses [J]. J Hematol Oncol，2018，11（1）：54-62.
[28] Pan JH，Zhou H，Zhao XX，et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma：Potential in diagnosis and antitumour treatments [J]. Int J Mol Med，2018，41（4）：1809-1816.